Introduction
============

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated mortality in the USA ([@b1-ol-0-0-5784]) and the seventh most common cause of cancer-associated mortality worldwide ([@b2-ol-0-0-5784]). However, it has a relatively low incidence rate, ranking eleventh among men and twelfth among women in developed countries ([@b2-ol-0-0-5784]). In America, it was estimated that 53,070 new patients will be diagnosed and 41,780 patients will succumb to PDAC in 2016 ([@b3-ol-0-0-5784]). Furthermore, in China, reports from the China\'s Disease Surveillance Point System showed that the age-adjusted mortality rate of patients with PDAC increased from 2.18 per 100,000 individuals in 1991 to 3.26 per 100,000 individuals in 2000 ([@b4-ol-0-0-5784]). Notably, the overall 5-year survival rate worldwide for this disease is \<5% ([@b5-ol-0-0-5784]), or 7% for the USA, despite being the most advanced nation in terms of medicine ([@b1-ol-0-0-5784]). Estimates indicate that PDAC will be second only to non-small-cell lung cancer as the leading cause of cancer-related mortality in the USA by 2030 ([@b6-ol-0-0-5784]). In addition, although complete surgical resection is the only therapy with a possibility for long-term survival ([@b7-ol-0-0-5784]), the 5-year survival rate of patients who have undergone surgical resection is only 15--20% ([@b8-ol-0-0-5784]). This extremely poor prognosis mostly results from its insidious onset and rapid progression. Furthermore, no effective screening test for predicting the prognosis of PDAC is available. Therefore, factors predictive of a poor disease prognosis are of interest. Lymph node metastasis, perineural invasion (PNI) and resection margins, which are conventional clinical and pathological parameters, were previously identified as significant variables ([@b9-ol-0-0-5784]--[@b11-ol-0-0-5784]). Increasingly, attention is being paid to tumor initiation/progress-associated molecules that are associated with the prognosis of PDAC ([@b12-ol-0-0-5784],[@b13-ol-0-0-5784]). However, more promising biomarkers are required.

Wilms tumor 1 (WT1)-associated protein (WTAP), which is a nuclear protein, was first identified by Little *et al* ([@b14-ol-0-0-5784]) in 2000 because of its specific interaction with WT1. However, WTAP has also been shown to have a close relationship with malignant tumors. For instance, WTAP was shown to be overexpressed in cholangiocarcinoma, in particular in patients with lymph node metastasis or vascular invasion ([@b15-ol-0-0-5784]). Further analysis of the relationship between WTAP and clinicopathological characteristics demonstrated that the expression level of WTAP was closely associated with the tumor-node-metastasis stage ([@b16-ol-0-0-5784]). In addition, *in vitro* assays showed that WTAP has an important role in the migration and invasion of cholangiocarcinoma cells, which was also demonstrated for glioblastoma ([@b16-ol-0-0-5784]). Notably, WTAP was overexpressed in glioblastoma and was associated with the prognosis of patients with glioblastoma ([@b16-ol-0-0-5784]). Besides solid tumors, an oncogenic role for WTAP was also observed in acute myeloid leukemia (AML) ([@b17-ol-0-0-5784]). WTAP expression was able to promote the proliferation and inhibit the differentiation of AML cells. However, to the best of our knowledge, no previous studies have investigated the relationship between WTAP and PDAC. Therefore, the present study aimed to evaluate the expression of WTAP in PDAC and its association with the clinicopathological factors and prognosis of patients with PDAC.

Materials and methods
=====================

### Patients and tissue samples

PDAC tissues and adjacent normal tissues were obtained from 145 patients who underwent radical surgical resection (R0) at Peking Union Medical College Hospital (Beijing, China) between September 2004 and December 2008. The present study was approved by the Peking Union Medical College Hospital Ethical Committee. Informed consent was obtained from all patients. The diagnosis of PDAC for all patients was confirmed pathologically, according to the World Health Organization criteria ([@b18-ol-0-0-5784]). Adjacent normal tissues were obtained from the resected specimen as far as possible from the cancer lesion. The clinical and pathological data included patient demographics (age and gender), tumor size, tumor location, degree of histological differentiation, tumor stage (T stage), lymph node stage (N stage) and complete follow-up records. The clinicopathological variables of the patients are shown in [Table I](#tI-ol-0-0-5784){ref-type="table"}.

### Tissue microarray (TMA) construction

TMAs were constructed using formalin-fixed, paraffin-embedded blocks of PDAC and adjacent normal tissues. Diagnosis was confirmed by a hematoxylin-eosin staining-based routine pathological examination. Following a review and screening of the representative tumor regions, two tissue cores for each patient were sampled using a 1.5-mm punch. TMA construction was performed using a manual tissue arrayer (Beecher Instruments, Inc., Sun Prairie, WI, USA).

### Immunohistochemical staining

TMA-based immunohistochemical staining for WTAP was performed in tissues from 145 patients with PDAC using a rabbit anti-human WTAP polyclonal antibody (cat. no. ab155655; Abcam, Cambridge, UK) and a two-step staining kit (EnVision™ Detection System, Peroxidase/DAB, Rabbit/Mouse; Dako, Glostrup, Denmark). The tissues were cross-sectioned (4-µm thick), mounted, deparaffinized with xylene (XILONG Chemical Co., Ltd., Shanghai, China) and rehydrated with a graded ethanol series (100, 95 and 75%), after which antigens were retrieved by autoclaving with 0.01 M citrate buffer at 95°C for 10 min. Slides were subsequently incubated with 3% hydrogen peroxide at 25°C for 10 min to block endogenous peroxidase activity, followed by incubation with the primary antibody (dilution, 1:100) overnight at 4°C. Following washing in PBS, the slides were incubated with horseradish peroxidase-labeled secondary antibody (ready to use; EnVision™ Detection System, Peroxidase/DAB, Rabbit/Mouse; Dako) and, after washing with PBS, the slides were stained with diaminobenzidine and then counterstained with hematoxylin. Normal rabbit serum (cat. no. ab7487; Abcam) at the same dilution was applied as the negative control.

### Staining evaluation

Two pathologists with no prior information of clinicopathological and survival data performed the staining evaluation using a light microscope. Controversies were resolved by reaching a consensus following a discussion. Nuclear and/or cytoplasmic brown coloration was defined as a positive signal. The two pathologists evaluated the percentage of positively stained cells and scored the intensity of tumor cell staining. The percentage of positive cells was classified into five grades: 0%, grade 0; 1--24%, grade 1; 25--49%, grade 2; 50--74%, grade 3; and 75--100%, grade 4. The staining intensity was classified into four grades: Primary score =0, grade 0; primary score \<1, grade 1; primary score ≥1 and \<1.5, grade 2; and primary score ≥1.5, grade 3. When comparing the expression level of cytoplasmic/nuclear WTAP between tumor tissues and non-tumor tissues using the Mann-Whitney U test, the product of the above two grades was used as the final score. When investigating the prognostic significance of the cytoplasmic/nuclear expression level of WTAP, the ratio of the product of the percentage of positively stained cells and the primary intensity score of tumor cell staining between tumor and non-tumor tissues for each corresponding patient was used (cytoplasmic: low, ratio \<1.8; high, ratio ≥1.8; nuclear: low, ratio \<5.0; high, ratio ≥5.0).

### Follow-up and evaluated variables

Follow-up after surgery was performed for all patients (median duration of follow-up, 13.2 months; range, 3--87 months). Eight general, clinical and pathological variables, including gender, age, tumor site, tumor size, grade, PNI and T/N stages, were evaluated.

### Statistical analyses

WTAP staining between the tumor and non-tumor tissues was compared using the Mann-Whitney U test. The χ^2^ test was used to assess the association between WTAP expression and clinicopathological variables. Overall survival was calculated using the Kaplan-Meier method and analyzed by the log-rank test. Cox regression (proportional hazard model) was used to perform a multivariate analysis of prognostic factors. Statistical analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Nuclear expression of WTAP in PDAC tissues and its association with clinicopathological features

Positive nuclear staining of WTAP was present in both tumor and non-tumor tissues ([Fig. 1A and B](#f1-ol-0-0-5784){ref-type="fig"}). The nuclear WTAP staining score in tumor tissues was significantly higher compared with that of non-tumor tissues (P\<0.001; [Fig. 2](#f2-ol-0-0-5784){ref-type="fig"}). As shown in [Table I](#tI-ol-0-0-5784){ref-type="table"}, high expression of WTAP in the nucleus was significantly associated with gender (P=0.010) and T stage (P=0.020).

### Cytoplasmic expression of WTAP in PDAC tissues and its association with clinicopathological features

Positive cytoplasmic WTAP signals were observed in both tumor and non-tumor tissues ([Fig. 1A and B](#f1-ol-0-0-5784){ref-type="fig"}). The cytoplasmic WTAP staining score in tumor tissues was significantly higher compared with that of non-tumor tissues (P\<0.001; [Fig. 3](#f3-ol-0-0-5784){ref-type="fig"}). As shown in [Table II](#tII-ol-0-0-5784){ref-type="table"}, high cytoplasmic expression of WTAP was significantly associated with gender (P=0.018), histological grade (P=0.047) and PNI (P=0.028).

### Prognostic significance of WTAP in PDAC

The prognostic significance of various clinicopathological factors in PDAC patients who underwent radical resection was investigated. For overall survival, univariate analyses demonstrated that patients with high nuclear WTAP expression had a significantly poorer overall survival (P\<0.001; [Fig. 4](#f4-ol-0-0-5784){ref-type="fig"}; [Table III](#tIII-ol-0-0-5784){ref-type="table"}). In addition, gender and N stage were also prognostic factors in the univariate analysis (P=0.006 and 0.004, respectively; [Table III](#tIII-ol-0-0-5784){ref-type="table"}). A multivariate Cox regression analysis identified nuclear WTAP expression as an independent prognostic indicator of PDAC (P=0.039; [Table III](#tIII-ol-0-0-5784){ref-type="table"}).

Discussion
==========

WTAP, which is a nuclear protein identified in 2000 ([@b14-ol-0-0-5784]), has mainly been described in the context of cell proliferation and apoptosis of vascular smooth muscle cells (VSMCs) ([@b19-ol-0-0-5784],[@b20-ol-0-0-5784]). Its ubiquitous expression pattern ([@b21-ol-0-0-5784],[@b22-ol-0-0-5784]) and highly conserved structure indicated that WTAP may act as a house-keeping gene. This was confirmed by the fact that WTAP was shown to be essential for the differentiation of endoderm and mesoderm in the mouse embryo and that WTAP-null and heterozygous mice died at E6.5 and at E10.5, respectively ([@b20-ol-0-0-5784]).

The WTAP gene was mapped to human chromosome 6q25-27 ([@b14-ol-0-0-5784]). Interestingly, human chromosome 6q25-27 has been associated with several malignancies, including ovarian cancer ([@b23-ol-0-0-5784]), renal cell carcinoma ([@b24-ol-0-0-5784]) and leukemia ([@b25-ol-0-0-5784]). In addition, as a closely related protein of WT1, which has been shown to be both an oncogene and a tumor suppressor gene ([@b26-ol-0-0-5784]), it is of interest to investigate whether WTAP is associated with malignances. Previous studies have suggested that WTAP may be a novel oncogene. WTAP was able to promote the migration and invasion of cholangiocarcinoma cells by enhancing the expression of matrix metalloproteinase (MMP) 7, MMP28, cathepsin H and mucin 1, which are enzymes that degrade extracellular matrix components ([@b15-ol-0-0-5784]). In addition, WTAP was overexpressed in glioblastoma and was associated with the prognosis of patients with glioblastoma ([@b16-ol-0-0-5784]). Through cDNA microarray experiments, several candidate genes downstream of WTAP, including C-C motif chemokine ligand (CCL) 2, CCL3, hyaluronan synthase 1 (HAS1), lysyl oxidase-like (LOXL) 1, MMP3 and thrombospondin 1 (THBS1), were identified ([@b16-ol-0-0-5784]). Chemokines, including CCL2 and CCL3, have been shown to promote the migration of cancer cells ([@b27-ol-0-0-5784],[@b28-ol-0-0-5784]). LOXL, which oxidizes lysine residues in collagens and elastin, has a promotive role in metastasis by remodeling the tumor microenvironment ([@b29-ol-0-0-5784]). Hyaluronic acid family proteins including HAS1 have been shown to regulate metastasis ([@b30-ol-0-0-5784]). THBS1 was a multifunctional matrix protein involved in the migration of cancer cells ([@b31-ol-0-0-5784]). Besides solid tumors, an oncogenic role for WTAP was also observed in AML ([@b17-ol-0-0-5784]): By regulating the mammalian target of rapamycin signaling pathway, WTAP promoted the proliferation and induced a differentiation block in AML cells.

To the best of our knowledge, no previous studies have investigated the relationship between WTAP expression and the clinicopathological variables and prognosis of patients with PDAC. The present study demonstrated that WTAP was expressed both in tumor and non-tumor tissues; however, the nuclear expression level of WTAP was significantly higher in tumor tissues than in non-tumor tissues, and high nuclear expression of WTAP was significantly associated with gender and T stage. Furthermore, nuclear WTAP expression was shown to be an independent prognostic indicator of PDAC. However, the function of WTAP in the nucleus remains unknown.

One possible mechanism is that WTAP is able to regulate the transcriptional activity of WT1 by binding to it. In VSMCs, it was shown that WT1 exerted its anti-proliferative and pro-apoptotic activities via the WTAP-WT1 axis, of which the target genes included amphiregulin ([@b32-ol-0-0-5784]), a potential VSMC mitogen ([@b33-ol-0-0-5784]), and B-cell lymphoma (Bcl)-2 ([@b34-ol-0-0-5784]), which has also been shown to exert an anti-apoptotic role in VSMCs ([@b35-ol-0-0-5784]). WT1 is a well-known tumor suppressor gene in Wilms\' tumor ([@b26-ol-0-0-5784]). However, data have accumulated regarding an oncogenic role for WT1 in various adult tumors, including colorectal ([@b36-ol-0-0-5784]), breast ([@b37-ol-0-0-5784]), desmoid ([@b38-ol-0-0-5784]), pancreatic ([@b39-ol-0-0-5784]) and brain tumors ([@b40-ol-0-0-5784]). The bi-directional control of the mesenchymal-epithelial transition ([@b41-ol-0-0-5784],[@b42-ol-0-0-5784]) may partially explain how WT1 is able to function as a tumor suppressor gene in some tissues and as a potential oncogene in others. Furthermore, the WTAP-WT1 axis may account for the different effects of WTAP in different cell types, as the function of WT1 is known to vary in different contexts ([@b26-ol-0-0-5784]). Therefore, it is likely that WTAP has an oncogenic role in PDAC via the WTAP-WT1 axis, although this requires further investigation.

Another possible mechanism is that WTAP is involved in pre-mRNA splicing, which has been reported in VSMCs ([@b43-ol-0-0-5784]). Approximately 94% of genes were estimated to be alternatively spliced in humans, driving the proteome diversity ([@b44-ol-0-0-5784],[@b45-ol-0-0-5784]). During oncogenesis and tumor progression, cells undergo various processes, including sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, reprogramming of energy metabolism and evading immune destruction ([@b46-ol-0-0-5784]). Importantly, it has been reported that alternative splicing regulates many of these processes ([@b47-ol-0-0-5784]). For instance, de4 epidermal growth factor receptor (EGFR), a splice variant of EGFR, which is a member of the receptor tyrosine kinases family and has a central role in cell proliferation and motility through downstream signaling mediators, functions as a receptor that was constitutively active and promoted proliferation in gliomas and prostate and ovarian cancer ([@b48-ol-0-0-5784]). In addition, alternative splicing of Bcl-x produced a short isoform that was pro-apoptotic, and a long isoform that was anti-apoptotic ([@b49-ol-0-0-5784]). The balance of these two isoforms affected different types of cancer cell lines and human cancer samples differently ([@b50-ol-0-0-5784]--[@b52-ol-0-0-5784]). ΔRon, which is a specific isoform of Ron generated by skipping of exon 11 by alternative splicing, conferred an increased motility on cancer cells and was upregulated in several types of cancers ([@b53-ol-0-0-5784]). Therefore, it is likely that WTAP plays an oncogenic role in the nucleus by regulating cancer-associated pre-mRNA splicing in PDAC.

The present study demonstrated that the cytoplasmic WTAP staining score of tumor tissues was significantly higher than that of non-tumor tissues, and high WTAP cytoplasmic expression was significantly associated with gender, histological grade and PNI. One possible mechanism for cytoplasmic WTAP to accelerate the PNI and dedifferentiation of PDAC cells is through its specific interaction with WT1. Although WT1 predominantly existed in the nucleus, a previous study demonstrated that WT1 underwent nucleocytoplasmic shuttling ([@b54-ol-0-0-5784]), which means WT1 may also participate in some cellular processes occurring in the cytoplasm. WT1 may be divided into two major isoforms, depending on the presence or absence of lysine-threonine-serine (KTS): +KTS and -KTS ([@b14-ol-0-0-5784]). Shuttling occurred with both the +KTS and the -KTS isoforms, which led to their association with actively translating polysomes ([@b55-ol-0-0-5784]). It is not yet clear what function is served by WT1 associating with the polysomes, but it adds a further dimension to the potential functions of the WTAP-WT1 axis in cancer formation and progression.

Another possible mechanism is its role in mRNA stabilization. In human umbilical vein endothelial cells, WTAP enhanced cyclin A2 mRNA stability by binding to its 3′-untranslated region (UTR) ([@b20-ol-0-0-5784]). However, other studies suggested that WTAP was able to accelerate the degradation of target mRNAs by promoting N6-methyladenosine (m6A) formation. In one study, WTAP was shown to form a complex with the methyltransferase-like (METTL) 3/METTL14 heterodimer to catalyze m6A formation ([@b56-ol-0-0-5784]). In another study, the C-terminal domain of YTH m6A RNA binding protein 2 selectively bound to m6A-containing mRNA, resulting in the translocation of the bound mRNA from the translatable pool to mRNA decay sites ([@b57-ol-0-0-5784]). These findings suggested that WTAP may negatively correlate with the stability of its target mRNAs. The regulation of mRNA stability has been recognized as an important process in the control of gene expression. The best-characterized cis-element that mediates mRNA degradation is the AU-rich element ([@b58-ol-0-0-5784]), which is present in the 3′-UTR of numerous mRNAs, including those of growth factors ([@b59-ol-0-0-5784]), oncogenes ([@b60-ol-0-0-5784]), cytokines ([@b61-ol-0-0-5784],[@b62-ol-0-0-5784]) and cell-cycle regulatory proteins ([@b63-ol-0-0-5784],[@b64-ol-0-0-5784]). Although WTAP has been shown to have a dual role in mRNA stability, the mRNAs of the above genes may be the downstream targets mediating its oncogenic role in the cytoplasm.

In conclusion, the results of the present study suggested that both nuclear and cytoplasmic WTAP was highly expressed in PDAC and that high nuclear expression of WTAP was a valuable molecular biomarker of a poor prognosis among PDAC patients.
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![Comparison of the nuclear WTAP expression staining scores between tumor and non-tumor tissues (Mann Whitney U test). Nuclear WTAP expression staining scores in tumor tissues: 5.8828±4.07823, nuclear WTAP expression staining scores in non-tumor tissues: 2.0759±2.40683. \*P\<0.001. WTAP, Wilms tumor 1-associated protein.](ol-13-04-2531-g01){#f2-ol-0-0-5784}

![Comparison of the cytoplasmic WTAP expression staining scores between tumor and non-tumor tissues (Mann-Whitney U test). Cytoplasmic WTAP expression staining scores in tumor tissues: 5.3724±3.07757, cytoplasmic WTAP expression staining scores in non-tumor tissues: 3.4828±2.37494. \*P\<0.001. WTAP, Wilms tumor 1-associated protein.](ol-13-04-2531-g02){#f3-ol-0-0-5784}

![Overall survival of patients with pancreatic ductal adenocarcinoma after surgical resection according to nuclear Wilms tumor 1-associated protein expression in tumor tissues. P=0.000.](ol-13-04-2531-g03){#f4-ol-0-0-5784}

###### 

Nuclear WTAP expression in tumor tissues and clinicopathological features of pancreatic ductal adenocarcinoma.

                             Nuclear WTAP expression        
  -------------------- ----- ------------------------- ---- -------
  Gender^b^                                                 0.010
    Male               85    37                        48   
    Female             54    12                        42   
  Age (years)                                               0.918
    ≥65                43    15                        28   
    \<65               95    34                        61   
  Tumor location                                            0.851
    Head               79    28                        51   
    Non-head           54    20                        34   
  Tumor size (cm)                                           0.290
    ≥4                 98    37                        61   
    \<4                39    11                        28   
  Histological grade                                        0.443
    G1--2              106   35                        71   
    G3--4              19    8                         11   
  T stage                                                   0.020
    T1--2              81    22                        59   
    T3                 56    26                        30   
  N stage                                                   0.512
    N0                 78    26                        52   
    N1                 54    21                        33   
  PNI                                                       0.687
    Present            69    26                        43   
    Absent             31    13                        18   

χ^2^ test. Total patient number does not equal 145 in all categories, as patient information was not available for all cases. WTAP, Wilms tumor 1-associated protein; G1, well-differentiated; G2, moderately-differentiated; G3, poorly-differentiated; G4, undifferentiated; T, tumor; N, lymph node; PNI, perineural invasion.

###### 

Cytoplasmic WTAP expression in tumor tissues and clinicopathological features of pancreatic ductal adenocarcinoma.

                             Cytoplasmic WTAP expression        
  -------------------- ----- ----------------------------- ---- -------
  Gender                                                        0.018
    Male               85    39                            46   
    Female             54    14                            40   
  Age (years)                                                   0.224
    ≥65                43    13                            30   
    \<65               95    39                            56   
  Tumor location                                                0.087
    Head               79    25                            54   
    Non-head           54    25                            29   
  Tumor size (cm)                                               0.417
    ≥4                 98    40                            58   
    \<4                39    13                            26   
  Histological grade                                            0.047
    G1--2              106   36                            70   
    G3--4              19    8                             11   
  T stage                                                       0.342
    T1--2              81    34                            47   
    T3                 56    19                            37   
  N stage                                                       0.754
    N0                 78    31                            47   
    N1                 54    20                            34   
  PNI                                                           0.028
    Present            69    29                            40   
    Absent             31    6                             25   

χ^2^ test. Total patient number does not equal 145 in all categories, as patient information was not available for all cases. WTAP, Wilms tumor 1-associated protein; G1, well-differentiated; G2, moderately-differentiated; G3, poorly-differentiated; G4, undifferentiated; T, tumor; N, lymph node; PNI, perineural invasion.

###### 

Predictors of OS in patients with pancreatic ductal adenocarcinoma after resection.

                                OS (univariate)   OS (multivariate)                                                 
  ----------------------------- ----------------- ------------------- -------------- ------- ------- -------------- -------
  Gender                                                                             0.006                          0.920
    Male                          85              13.00±1.35          10.36--15.64           1.036   0.520--2.064   
    Female                        54              18.90±6.99          5.20--32.60            1                      
  Age (years)                                                                        0.842                          0.613
    ≥65                           43              12.30±3.85          4.75--19.85            1.193   0.603--2.358   
    \<65                          95              13.20±1.21          10.84--15.56           1                      
  Tumor location                                                                     0.337                          0.087
    Head                          79              13.70±2.85          8.12--19.29            1.699   0.926--3.119   
    Non-head                      54              11.00±1.85          7.38--14.62            1                      
  Tumor size (cm)                                                                    0.662                          0.721
    ≥4                            98              13.00±2.43          8.24--17.76            1.119   0.605--2.070   
    \<4                           39              15.00±3.08          8.97--21.03            1                      
  Histological grade                                                                 0.535                          0.284
    G3--4                       106               13.00±2.68          7.74--18.26            1.493   0.717--3.106   
    G1--2                         19              14.30±2.35          9.70--18.90            1                      
  T stage                                                                            0.060                          0.051
    T3                            81              12.50±1.16          10.24--14.76           1.783   0.988--3.185   
    T1--2                         56              16.80±2.99          10.93--22.76           1                      
  N stage                                                                            0.004                          0.189
    N1                            78              11.00±1.06          8.93--13.27            1.468   0.827--2.611   
    N0                            54              18.90±2.92          13.56--24.24           1                      
  PNI                                                                                0.409                          0.245
    Present                       69              12.70±1.53          9.70--15.70            1.456   0.773--2.739   
    Absent                        31              17.40±4.14          9.28--25.52            1                      
  Nuclear WTAP expression                                                            0.000                          0.039
    High                          45              11.00±1.54          7.98--14.02            1.855   1.033--3.333   
    Low                           83              18.80±3.09          12.75--24.85           1                      
  Cytoplasmic WTAP expression                                                        0.256                          0.876
    High                          53              17.00±5.20          6.81--27.19            1.054   0.541--2.056   
    Low                           75              12.70±1.43          9.90--15.50            1                      

Log-rank test

Multivariate Cox regression test. Total patient number does not equal 145 in all categories, as patient information was not available for all cases. OS, overall survival; SE, standard error; RR, relative risk; CI, confidence interval; G1, well-differentiated; G2, moderately-differentiated; G3, poorly-differentiated; G4, undifferentiated; T, tumor; N, lymph node; PNI, perineural invasion; WTAP, Wilms tumor 1-associated protein; 95% CI, 95% confidence interval; P, P-value.
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